{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:33:17Z","timestamp":1779168797725,"version":"3.51.4"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,3,28]],"date-time":"2003-03-28T00:00:00Z","timestamp":1048809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:<\/jats:bold> Intravesical instillation of bacillus Calmette\u2010Gu\u00e9rin (BCG) is the most efficient strategy for prophylaxis of superficial bladder cancer recurrence. Adverse effects of BCG are major obstacles, but the reduction of BCG dose could minimize these effects. The efficacy and adverse effects of half\u2010dose (40\u2003mg) BCG, Tokyo 172 strain, were prospectively evaluated.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 93 patients with superficial bladder cancer (pTa or pT1) were sequentially assigned to receive either 40 or 80\u2003mg of BCG after transurethral resection. BCG was administered weekly for 6\u2003weeks postoperatively. Eighty patients observed longer than 12\u2003months after BCG therapy (41, 40\u2003mg group; 39, 80\u2003mg group) were analyzed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> BCG therapy course was completed in 71 patients. Tumor recurrence was recognized in 11 of 40 patients in the 40\u2003mg group and in 5 of 31 patients in the 80\u2003mg group. There was no significant difference in tumor recurrence rate between the two groups (<jats:italic>P<\/jats:italic>\u2003=\u20030.547). BCG therapy was withdrawn in 1 patient in the 40\u2003mg group and in 8 patients in the 80\u2003mg\u2010group because of BCG\u2010related adverse effects. The morbidity of BCG\u2010related toxicity was significantly higher in the 80\u2003mg group.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Half\u2010dose of BCG Tokyo 172 strain had a similar efficacy and its toxicity was signi\u00adficantly lower compared to the standard dose. Thus, half\u2010dose of this strain might be suitable, at least for initial BCG therapy, for the prophylaxis of bladder cancer recurrence. Further study would be necessary to clarify the efficacy of low\u2010dose instillation in high\u2010risk patients.<\/jats:p>","DOI":"10.1046\/j.0919-8172.2003.00607.x","type":"journal-article","created":{"date-parts":[[2004,12,26]],"date-time":"2004-12-26T02:29:43Z","timestamp":1104028183000},"page":"183-189","source":"Crossref","is-referenced-by-count":33,"title":["Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low\u2010dose bacillus Calmette\u2010Gu\u00e9rin for superficial bladder cancer recurrence"],"prefix":"10.1111","volume":"10","author":[{"given":"AKIRA","family":"IRIE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOYOAKI","family":"UCHIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIDEYUKI","family":"YAMASHITA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KAZUMASA","family":"MATSUMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKEFUMI","family":"SATOH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIDESHIGE","family":"KOH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SATORU","family":"SHIMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASATSUGU","family":"IWAMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHIRO","family":"BABA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,3,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37707-8"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose\u2013response of bacillus Calmette\u2010Gu\u00e9rin in the treatment of superficial bladder cancer","volume":"147","author":"Morales A","year":"1992","journal-title":"J. Urol."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80115-0"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02552138"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000475203","article-title":"Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO","volume":"27","author":"Martinez\u2010Pineiro JA","year":"1995","journal-title":"Eur. Urol."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65458-2"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000019664"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67973-6"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200102000-00011"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53354-6"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)46976-X"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1992.tb15486.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.1997.tb00160.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930715)72:2<558::AID-CNCR2820720237>3.0.CO;2-H"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)55763-8"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00067-8"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65157-9"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36924-0"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000463883","article-title":"\u2018Solitary\u2019 Ta\u2010T1, G1 bladder tumour: History and long\u2010term prognosis","volume":"18","author":"Mufti GR","year":"1990","journal-title":"Eur. Urol."},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2646"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63731-5"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0919-8172.2003.00607.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.0919-8172.2003.00607.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T05:22:07Z","timestamp":1697174527000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.0919-8172.2003.00607.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,28]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1046\/j.0919-8172.2003.00607.x"],"URL":"https:\/\/doi.org\/10.1046\/j.0919-8172.2003.00607.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3,28]]}}}